Most Popular Stories
- CDC: H1N1 cases down in some parts of U.S.
- Initial 'meaningful use' standards to be simple, as deadline is in sight
- Disparity researchers still stumped on colon cancer outcome differences
- Conservatives on Hill say individual mandate is unconstitutional
- Groups recommend less prevention for breast, cervical cancer screenings
- Open-source EMR opens doors to quality care
Featured Jobs
-
Ob/Gyn Job in California
StaffPointe, LLC - Bay area, CA -
RN Mgr Adult/Geri Psych Prog Job in MI
StaffPointe, LLC - south central, MI -
Orthopedic Surgery Job in Massachusetts
StaffPointe, LLC - west, MA -
Oncologist Job in Indiana
StaffPointe, LLC - east central, IN -
Cardiologist Job for North Carolina
StaffPointe, LLC - near coast, NC
Events
- Harvard Business School 7th Healthcare Conference
January 30, 2010 - Security Audits: Is Your Organization Prepared and In Compliance?
Dec.3 at 12 pm CT
Paid Research Reports
- Pricing and Reimbursement in Key Asia Pacific Markets
- Delivery Mechanisms for Large Molecule Drugs: Successes and failures of leading technologies and key drivers for market success
- The Cardiovascular Market Outlook to 2013: Competitive landscape, global market analysis and pipeline analysis
- Intellectual Property and Outsourcing in China: Minimizing risk whilst maximizing return on investment
- Health Care Equipment & Supplies: Global Industry Guide
- 2009 Trends to Watch: Healthcare Technology
FEATURES >> YouTube | Top acute-care hospitals | Women in Health IT | Top BlackBerry Apps | Commentary
TOPICS >> Stimulus | Health Reform | CMS News | Finance | EMRs | Mobile Healthcare | Hospital Leadership Blog
Free Newsletter
FierceHealthcare is the leading source of healthcare management news for healthcare industry executives. Join 46,000+ healthcare industry insiders who get FierceHealthcare via daily email. Sign up today!
Popular Topics
- Medicare
- health plans
- Centers for Medicare and Medicaid Services (CMS)
- Insurance
- Electronic Medical Records (EMRs)
- Food and Drug Administration (FDA)
- Department of Health and Human Services (HHS)
- Medicaid
- American Medical Association (AMA)
- healthcare system
- health reform
- prescription drugs
- pharmaceutical companies
Letter: Is limiting industry gifts a smart policy?
In a perfect world the policy made sense, but in the real world, this is another policy that some bio-ethicist who has nothing better to do dreamt up in his office.
The AMA was wrong years ago on this. For example, pharmaceutical companies can no longer support Continuing Medical Education (CME) dinner meetings if a spouse is to attend. The net result is that I do not attend these functions. I do not want these events to be another evening away from my family besides night calls. So the turnout for these functions have dropped dramatically. The flip side is that I do not have the slightest clue what products the pharmaceutical companies make, so there is the big hole in the "undue influence” argument.
The Society of Critical Care dropped pharmaceutical industry support for providing lunch at their annual meeting in order to avoid any possibility of being improperly influenced. The net result is the exhibit hall is like a ghost town during lunch hours whereas in the years before this policy was adopted the hall was usually full. I am equally helpless in telling you who was paying for lunch boxes in the prior years. This type of overly-cautious policy is detrimental to everyone. Pharma companies are not willing to pay high fees to rent exhibit hall space if no physician is around to talk to them. And we as physicians are missing the chance to be exposed to some genuinely new products at these meeting.
This is why I would never be a member of the AMA. Organized medicine believes in appearance and superficialities and not in common sense.
Yours truly,
Mike Wei, M.D.
Related Stories
- Drugmakers face direct-to-consumer ad ban
- States tighten screws on pharma marketers
- Study: Pharma disclosure laws not working
- MDs, vendors clash over EMR access
- Debate surrounds elective angioplasties
- Study: Medical boards too lenient on MDs
- Reports suggest that Merck downplayed Vioxx risks
- Avandia slammed by more studies
- Data providers challenge prescription-privacy laws
- Flood of new MDs overwhelms TX board
Home
| Subscribe | Advertise | Mobile Edition | RSS |
Privacy
| Site Map | List in Marketplace | Supplier MarketplaceTHE FIERCEMARKETS NETWORKFierceFinance | FierceFinanceIT | FierceComplianceIT | FierceHealthcare | FierceHealthFinance | FierceHealthIT | Hospital Impact | FierceMobileHealthcare | FierceCIO | FierceCIO:TechWatch | FierceContentManagement | FierceMobileIT | FierceGovernmentIT | FierceBiotech | FierceBiotech Research | FiercePharma | FierceVaccines | FierceBiotechIT | FiercePharma Manufacturing | FierceIPTV | FierceOnlineVideo | FierceTelecom | FierceVoIP | FierceBroadbandWireless | FierceDeveloper | FierceMobileContent | FierceWireless | FierceWireless:Europe© 2009 FierceMarkets, Inc. All rights reserved. |
![]() |





